SANOFI news, videos and press releases
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
- Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
- Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
- Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
- Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
- Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
- Press Release: Sanofi and CD&R sign Opella share purchase agreement
- Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
- Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
- Press Release: Sanofi announces buy back of shares from L’Oréal
- Sanofi: Information concerning the total number of voting rights and shares - December 2024
- Press Release: Opella reaches study milestone for Cialis
- Sanofi: Information concerning the total number of voting rights and shares – November 2024
- Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
- Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
- Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
- Sanofi: Information concerning the total number of voting rights and shares - October 2024
- Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
- Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
- Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
- Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
- Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
- Press Release: Availability of the Q3 2024 Aide mémoire
- Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
- Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
- Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
- Sanofi: Information concerning the total number of voting rights and shares - August 2024
- Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
- Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
- Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
